AstraZeneca’s anti-platelet drug Brilinta has been cleared in the US for a major new indication, preventing a first heart attack or stroke in high-risk patients with coronary artery disease (CAD).
AstraZeneca's antiplatelet drug Brilinta has met its objectives in a 21,000-patient Phase III trial that could help the company meet its lofty ambitions for the drug. Updated results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback